RT Journal Article
SR Electronic
T1 Evaluation of spike protein antigens for SARS-CoV-2 serology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.27.21250382
DO 10.1101/2021.01.27.21250382
A1 Jagtap, Suraj
A1 Ratnasri, K
A1 Valloly, Priyanka
A1 Sharma, Rakhi
A1 Maurya, Satyaghosh
A1 Gaigore, Anushree
A1 Ardhya, Chitra
A1 Biligi, Dayananda S.
A1 Desiraju, Bapu Koundinya
A1 Mouli Natchu, Uma Chandra
A1 Kumar Saini, Deepak
A1 Roy, Rahul
YR 2021
UL http://medrxiv.org/content/early/2021/01/29/2021.01.27.21250382.abstract
AB Background Spike protein domains are being used in various serology-based assays to detect prior exposure to SARS-CoV-2 virus. However, there has been limited comparison of human antibody titers against various spike protein antigens among COVID-19 infected patients.Methods We compared four spike proteins (RBD, S1, S2 and a stabilized spike trimer (ST)) representing commonly used antigens for their reactivity to human IgG antibodies using indirect ELISA in serum from COVID-19 patients and pre-2020 samples. ST ELISA was also compared against the EUROIMMUN IgG ELISA test. Further, we estimated time appropriate IgG and IgA seropositivity rates in COVID-19 patients using a panel of sera samples collected longitudinally from the day ofonset of symptoms (DOS).Results Among the four spike antigens tested, the ST demonstrated the highest sensitivity (86.2%; 95% CI: 77.8-91.7%), while all four antigens showed high specificity to COVID-19 sera (94.7-96.8%). 13.8% (13/94) of the samples did not show seroconversion in any of the four antigen-based assays. In a double-blinded head-to-head comparison, ST based IgG ELISA displayed a better sensitivity (87.5%, 95%CI: 76.4-93.8%) than the EUROIMMUN IgG ELISA (67.9%, 95% CI: 54.8-78.6%). Further, in ST-based assays, we found 48% and 50% seroconversion in the first six days (from DOS) for IgG and IgA antibodies, respectively, which increased to 84% (IgG) and 85% (IgA) for samples collected ≥22 days DOS.Conclusions Comparison of spike antigens demonstrates that spike trimer protein is a superior option as an ELISA antigen for COVID-19 serology.HighlightsSpike trimer displays the highest antibody titer in SARS-CoV-2 infections among spike protein antigens.Spike trimer IgG ELISA displays a sensitivity of 50% within six days and 86.2% after 14 days from onset of symptoms.IgA and IgG responses to spike trimer antigen were comparable and concomitant in time after infection.16% (IgG) and 15% (IgA) of COVID-19 RT-PCR positive patients did not seroconvert even after 21 days from onset of symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Indian Institute of Science and Corporate Social Responsibility funding by Capgemini India. Funding agencies had no role in the design, execution, interpretation and publication decision of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the Institute Human Ethics Committee at the Indian Institute of Science, Bangalore (1-12062020E/10-14032018) and Ethics Committee of Bangalore Medical College and Research Institute, Bangalore (BMCRI/PS/02/2020-21) and Institutional Ethics Committee at Translational Health Science and Technology Institute, Faridabad (THS 1.8.1/(91) 13.1.2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. Additional raw and derived data supporting the findings of this study are available from the corresponding author [RR] on request.